

FOI 2121

18.01.2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	93
• Adalimumab [Humira]	35
• Adalimumab Biosimilars	504
• Apremilast [Otezla]	1
• Baricitinib [Olumiant]	55
• Bimekizumab [Bimzelx]	1
• Certolizumab [Cimzia]	71
• Etanercept [Enbrel]	11
• Etanercept Biosimilars	200
• Filgotinib [Jyseleca]	0
• Golimumab [Simponi]	80
• Guselkumab [Tremfya]	6
• Infliximab [Remicade]	1
• Infliximab Biosimilars	30
• Ixekizumab [Taltz]	46
• Risankizumab [Skyrizi]	1
• Rituximab [MabThera]	0
• Rituximab Biosimilars	106
• Sarilumab [Kevzara]	17
• Secukinumab [Cosentyx]	135
• Tocilizumab [Ro Actemra]	43
• Tocilizumab Biosimilars	0
• Tofacitinib [Xeljanz]	12
• Upadacitinib [Rinvoq]	17
• Ustekinumab [Stelara]	0

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs:

Adalimumab [Humira]	15
Adalimumab Biosimilars	149
Certolizumab [Cimzia]	27
Etanercept [Enbrel]	0
Etanercept Biosimilars	32
Golimumab [Simponi]	36
Infliximab [Remicade]	0
Infliximab Biosimilars	10
Ixekizumab [Taltz]	9
Secukinumab [Cosentyx]	53
Tofacitinib [Xeljanz]	0
Upadacitinib [Rinvoq]	2

Email: Foi.Team@Southerntrust.hscni.net